CoChat

The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments

Open access
Connick, Peter, Kolappan, Madhan, Patani, Rickie, Scott, Michael A, Crawley, Charles, He, Xiao-Ling, Richardson, Karen, Barber, Kelly, Webber, Daniel J, Wheeler-Kingshott, Claudia AM, Tozer, Daniel J, Samson, Rebecca S, Thomas, David L, Du, Ming-Qing, Luan, Shi L, Michell, Andrew W, Altmann, Daniel R, Thompson, Alan J, Miller, David H, Compston, Alastair, Chandran, Siddharthan · 2011 · Trials
Cited by 119

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

BACKGROUND: No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of treatment with a candidate cell-based therapy, and will inform the wider challenge of designing early phase clinical trials to evaluate putative neuroprotective therapies in progressive MS. Illustrated by the MSCIMS trial protocol, we describe a novel methodology based on detailed assessment of the anterior visual pathway as a model of wider disease processes--the "sentinel lesion approach". METHODS/DESIGN: MSCIMS is a phase IIA study of autologous mesenchymal stem cells (MSCs) in secondary progressive MS. A pre-test : post-test design is used with healthy controls providing normative data for inter-session variability. Complementary eligibility criteria and outcomes are used to select participants with disease affecting the anterior visual pathway. RESULTS: Ten participants with MS and eight healthy controls were recruited between October 2008 and March 2009. Mesenchymal stem cells were successfully isolated, expanded and characterised in vitro for all participants in the treatment arm. CONCLUSIONS: In addition to determining the safety and feasibility of the intervention and informing design of future studies to address efficacy, MSCIMS adopts a novel strategy for testing neuroprotective agents in MS--the sentinel lesion approach--serving as proof of principle for its future wider applicability. TRIAL REGISTRATION: ClinicalTrials.gov (NCT00395200).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1745-6215-12-62

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 119

Metadata

Authors
Connick, P., Kolappan, M., Patani, R., Scott, M. A., Crawley, C., He, X.-L., Richardson, K., Barber, K., Webber, D. J., Wheeler-Kingshott, C. A., Tozer, D. J., Samson, R. S., Thomas, D. L., Du, M.-Q., Luan, S. L., Michell, A. W., Altmann, D. R., Thompson, A. J., Miller, D. H., Compston, A., & Chandran, S.
Venue
Trials
Published
2011-03-02
Volume
12
Issue
1
Pages
62-62
ISSN
1745-6215 (ISSN-L)
OpenAlex
W2108538059
Cited by
119
References
1
FWCI
8.00
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. https://app.cochat.ai/papers/10.1186/1745-6215-12-62
The paper
Connick, P., Kolappan, M., Patani, R., Scott, M. A., Crawley, C., He, X.-L., Richardson, K., Barber, K., Webber, D. J., Wheeler-Kingshott, C. A., Tozer, D. J., Samson, R. S., Thomas, D. L., Du, M.-Q., Luan, S. L., Michell, A. W., Altmann, D. R., Thompson, A. J., Miller, D. H., . . . Chandran, S. (2011). The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. Trials. https://doi.org/10.1186/1745-6215-12-62

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.